ACADIA Pharmaceuticals, Inc. And Meiji Seika Kaisha, Ltd. Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Meiji Seika Kaisha, Ltd. (TSE:2202) today announced that they have established a collaboration to develop and commercialize a novel class of pro-cognitive drugs to treat patients with schizophrenia and related disorders in Japan and several other Asian countries. The collaboration will focus on developing a product candidate, which was discovered by ACADIA and has been nominated by the parties for IND-track development.